Aktiesnakken — Juni 2013
-
Lidt daratumumab: Dr. Lokhorst reported that the responses are durable. At a median follow-up of 3.8 months, median progression-free survival for patients receiving doses of at least 4 mg/kg has not been reached. However, after only 8 cycles, "we saw progression-free survival of more than 8 months, even after treatment was stopped," he noted.
-
tjaaa. den kunne jeg godt købe mig ind i.
-
jeg har hele tiden troet at microsoft kunne være køberen
-
perfekt match
-
Dara sakset fra artikel på medscape http://www.medscape.com/viewarticle/806458?src=sttwit
-
ja og noget finsk stolthed, Svært at komme helt på toppen og så blive købt ud på bunden
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind